In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays ...

LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...

In 2023, semaglutide emerged as the top-selling drug in the USA, generating $13.8 billion in sales. Read more.

In 2024, coverage for obesity drugs increased to 44% among employers with 500 or more workers, compared to 41% last year, the ...

Taking anti-obesity drugs has led some U.S. adults to throw away more food than they tossed before starting the medications, a new study has found.

The head of Walmart's $55-billion health and wellness division, who oversaw the company's failed push into clinics, is ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 in ...

The US economy could see a surge in growth as more people start to take GLP-1 weight-loss drugs. Goldman Sachs predicted that ...

In today’s health headlines, can GLP-1 drugs reverse prediabetes? Plus, how to reduce food noise and stick to weight loss ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.